Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic, Oncology, and CNS Delivery Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for INSR/CD220 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | INSR (Isoform A & B) ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View INSR Products |
| Gene Delivery | INSR Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native heterotetramer conformation; ideal for internalization and signaling assays. |
View INSR Products |
| Benchmark Ab | Anti-INSR (Clinical Benchmark / Allosteric Antagonist Clone) Recombinant positive control for binding and inhibition assays. |
View INSR Products |
| Validator | INSR siRNA Set For knockdown verification and assay specificity controls. |
View INSR Products |
| Related Target A: IGF1R | Homologous tyrosine kinase receptor (64% extracellular domain identity); frequent heterodimerization and compensatory signaling with INSR. Crucial counter-screening target. | View IGF1R Products |
| Related Target B: TfR1 | Alternative receptor for Blood-Brain Barrier (BBB) transcytosis platforms. | View TfR1 Products |
| Related Target C: IGF1 | Ligand for cross-pathway functional assays. | View IGF1 Products |
| Related Target D: IGF2 | High-affinity ligand for IR-A isoform; essential for ligand competition and hybrid receptor studies. | View IGF2 Products |
Key Mutations & Functional Domains
INSR (CD220) contains three Fibronectin type-III domains in its extracellular region (Fibronectin type-III 1, 2, 3), critical for ligand binding and receptor activation. Key mutations reported in UniProt P06213 include rs7508518 (silent variant), the RMS mutation which impairs transport to the plasma membrane and reduces affinity to bin, and the LEPRCH/Verona-1 mutation (dbSNP:rs121913152) associated with insulin resistance. These genetic variations are important considerations for drug discovery programs targeting INSR.
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Specificity (INSR-A vs INSR-B) | Distinct Isoform A and Isoform B extracellular domains available, Sequence Verified for precise structural fidelity. |
| Subfamily Counter Screening (IGF1R) | Human, cyno, mouse IGF1R homolog proteins available; >95% purity, mass spec verified. Essential for cross-reactivity profiling. |
| Cross-species Evaluation | Human/Mouse/Cynomolgus INSR ECD-Fc proteins with >95% sequence conservation; Endotoxin Controlled (<1EU/ug) for in vivo translation. |
| ADC Internalization Validation | Lentivirus particles for stable INSR-overexpression cell lines; Preserves native conformation for flow cytometry-based internalization assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and validated siRNA included for assay calibration and specificity checks. |
| False Positives Reduction | Validated INSR siRNA included for knockdown verification and background noise reduction. |
Live INSR/CD220 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for INSR/CD220 therapeutics is intensifying. Historically dominated by peptide agonists (insulin analogues) for diabetes, major players are shifting focus toward monoclonal antibodies and bispecific platforms. A massive new frontier is the utilization of INSR as a transcytosis target for Blood-Brain Barrier (BBB) crossing, enabling CNS delivery of large molecules. Simultaneously, INSR/IGF1R bispecific antibodies are being developed for cancer co-inhibition, and ADCs target INSR-overexpressing solid tumors. The next wave of R&D is targeting optimal binding affinities that allow brain penetration without systemic metabolic disruption, as well as tissue-selective allosteric modulators to avoid hypoglycemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Carrier mAbs / Bispecifics | Roche, Denali, JCR Pharma | CNS Diseases (BBB Crossing) | pH-dependent Binding Assay (Need high-purity ECD-Fc) |
| Agonist / Antagonist mAbs | Novo Nordisk, Eli Lilly | Insulin Resistance, Oncology | Isoform Selectivity (Need INSR-A vs INSR-B Proteins) |
| Bispecific Ab (INSR/IGF1R) | Hanmi, Sanofi | Cancer (co-inhibition) | Cross-reactive binding validation (Need Human INSR + IGF1R panel) |
| ADC | Emerging Biotech | INSR-high Solid Tumors | Internalization Assay (Need high-purity ECD-Fc) |
| Allosteric Modulator | Novo Nordisk, Eli Lilly | Type 2 Diabetes | Conformational Selectivity Assay (Need Full-length Lentivirus) |
| Peptides / Small Mol | Sanofi, Pfizer | Diabetes, Rare Metabolic | Receptor Activation (Need Lentivirus for Stable Cell Lines) |